Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
about
Patient-derived tumour xenografts as models for oncology drug developmentThe value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersDual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal CancersOne mouse, one patient paradigm: New avatars of personalized cancer therapyTranslating genomic profiling to gastrointestinal cancer treatment.The future of patient-derived tumor xenografts in cancer treatment.Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.Biology of colorectal cancer.The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphomaRas/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.High-dimensional omics data analysis using a variable screening protocol with prior knowledge integration (SKI)Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants.Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivityAntitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal CancerOvercoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.Signaling pathways as therapeutic targets in biliary tract cancer.Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding.DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype.Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerResistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.Inhibition of metadherin sensitizes breast cancer cells to AZD6244.Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinibβ-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
P2860
Q24604068-B84A67AD-0E5A-4147-B24B-9AD4E5B6DCAEQ26747403-611E2511-2556-43F8-A821-7D9E7D9B4F18Q26781362-9711284C-DAE3-4CC2-9E63-6698A43BA994Q27023342-12472288-8D0D-4C04-BA34-A68A3E085CFAQ30239109-54997E85-9366-4166-B9EC-102C1C4563DAQ33361578-8C7404CF-B068-4005-B064-986538F5E25CQ34273541-ED24E260-658E-41E4-90AC-02FC6709E1CBQ34417585-E1C08252-A317-4AE3-AC1A-197E6CD3F4A1Q34669618-F8C110A6-4AB9-45B3-BC30-E717F3B481A7Q35140947-ABA2B1A5-DE3F-4E0A-94CE-FA70078DB17CQ35679353-ECCE7B2F-684A-4F11-8DCB-99BC498EFCD0Q35934963-A74D8A59-0133-40E8-B1F0-FE48AE1A2395Q36242926-ED8950B9-408A-4E94-9F78-A70DE50064B2Q36268787-ED7C8F0A-4641-4A28-86CC-752F9305B678Q36351612-CFA9DE5E-E6DF-4105-BD7A-4213B0A8BFD9Q36382520-76E3A5B2-546D-4AF0-A08A-ED5AA6BB0F9BQ36544152-2E811C6F-8F96-48A2-91F2-2FD2085EA01EQ36708157-8AE4D663-8494-4BB5-9E51-E11ECFC22BE0Q37349748-681A971A-CA72-47EA-84DE-6C59CECA2AEAQ37421431-066AA534-333F-4D79-94C6-06D8C6C2E1ECQ38084846-FB9AEFC3-3ED4-40F4-96A7-A46CE5925A0CQ38238605-6120BE75-6B08-4C97-8B61-6360CC6EB516Q38402255-CDF186A3-5C91-4171-B884-10ECCB8CEB59Q38585847-57F5326E-472F-41BF-AAFC-1F1C0343938FQ38744494-63C0110F-4A79-4055-93DD-41B716B30045Q38747573-FE41EB86-9FBD-4458-BE60-24FCD8B62461Q38841033-D77715D1-505C-4A98-B5A6-CAB889E131EEQ38981469-C2FE7928-39C4-4579-AB32-0037331D39BDQ39122119-BFAF2015-7301-476D-B77D-325B676495B9Q39140763-80E16BFB-937C-414A-B01F-65545C938A16Q39224151-63CC4A4E-B5E0-432E-9ECE-9F554B9FA034Q39354437-854271C4-6994-4DB4-B08E-80F53EF683E2Q39396267-EF9EA91E-FC23-42BF-9C9F-AE7657819579Q41697013-9837E366-71C7-48E4-ACD4-1F3EBE73B1C5Q49547317-19EDC938-4FB5-4898-B741-FD794889E371Q50296864-2DA2ED73-D0E7-49B9-8574-91AD729DC5E6Q53765363-DA0FFDB7-B6DE-4F49-B03D-5B20E5319DA8Q57156789-7F307A16-BF79-40E1-8CB8-B6AEFE9745CA
P2860
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of predictive m ...... ras-mutated colorectal cancer.
@en
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib
@nl
type
label
Identification of predictive m ...... ras-mutated colorectal cancer.
@en
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib
@nl
prefLabel
Identification of predictive m ...... ras-mutated colorectal cancer.
@en
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib
@nl
P2093
P2860
P1476
Identification of predictive m ...... -ras-mutated colorectal cancer
@en
P2093
Anna Spreafico
Gillian N Kulikowski
Heather M Selby
John J Arcaroli
John J Tentler
M Pia Morelli
Maria I Kachaeva
S Gail Eckhardt
Sara A Flanigan
Stephen Leong
P2860
P304
P356
10.1158/1535-7163.MCT-10-0376
P577
2010-10-05T00:00:00Z